Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting
Post# of 421
(Total Views: 162)
Posted On: 04/05/2023 5:33:29 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform
- Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology
- The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results
- This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications
- These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)
- Currently, Lexaria is prioritizing research on DehydraTECH-CBD as a potential treatment for hypertension
Recent advancements in drug delivery techniques have improved, among others, the efficiency and safety of therapeutic treatments and active pharmaceutical ingredients (“APIs”). In fact, analyzing these improvements through the findings obtained by Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, demonstrates the progress is remarkable. Headquartered in Kelowna, British Columbia, the company developed and patented the DehydraTECH(TM) drug delivery platform technology, which is essentially an additional step easily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical lipophilic (fat-soluble) products.
“This step involves mixing the active ingredient as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors,” explains Lexaria’s website (https://nnw.fm/N4ThD ).
According to the company’s extensive studies, its patented DehydraTECH(TM) technology has been shown to enhance the bioavailability (the proportion of the ingested drug that enters the bloodstream) of APIs and increase brain absorption by up to 17x, with the effects felt in minutes (https://nnw.fm/1yBkk ). Other proven benefits include the fact that APIs processed using the technology platform are rendered largely flavorless and odorless, meaning manufacturers no longer have to add sweeteners or chemical masking agents. As a result and using DehydraTECH, they can create low-sugar products with fewer calories while avoiding the use of excessive artificial sweeteners. This is particularly positive, considering that recent studies suggest that consumption of excessive artificial sweeteners predisposes consumers to elevated blood sugar levels and raises their risk of developing stroke or heart disease (https://nnw.fm/zbozv ).
The above DehydraTECH-related findings are part of Lexaria’s extensive repository of positive results generated by its ongoing research and development (“R&D”) program. This program focuses on the development of product candidates across four main segments, which are intended to eventually serve as the platform’s commercialization avenues. These include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed nicotine delivered via non-combustive methods; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules, including antiviral drugs, hormone treatment, phosphodiesterase inhibitors, and more; and hemp-derived CBD applications for consumer packaged goods (“CPG”).
To date, Lexaria has undertaken multiple studies aimed at improving the commercialization prospects of the platform. “Our applied R&D programs completed since [our up-list to the Nasdaq exchange and capital raise in 2021] have yielded almost entirely positive results – a crucial accomplishment as we prepared to use those results to reinforce our outreach strategy to potential corporate partners,” CEO Chris Bunka stated in his annual letter to shareholders published January 2023 (https://nnw.fm/IBJEn ).
Bunka added that the applied R&D “is paying off in spades” because the company is currently engaged in active discussions with several multi-billion dollar companies around the world for the potential use of its DehydraTECH technology in their commercial products pursuits. And while the company cannot disclose the identities of these potential partners prior to the signing of definitive agreements, stakeholders and shareholders can, in the meantime, focus on the positive results of its R&D program, which are bellwethers of potential success.
For instance, in a recent diabetes animal model study, DIAB-A22-1, Lexaria reported at least three positive outcomes, including weight loss in obese diabetic-conditioned animals, a statistically significant improvement in locomotor activity, statistically significant reductions in triglyceride levels (high levels in the blood can suggest the onset of diabetes), and increased levels of HDL cholesterol, the ‘good’ kind of cholesterol (https://nnw.fm/KQjBK ).
These findings are the latest in a series of studies evaluating DehydraTECH-CBD as a potential treatment for a number of conditions, including diabetes, dementia, epilepsy, and hypertension, with the latter being the company’s primary and most advanced R&D program in this pipeline. To date, Lexaria has undertaken five human clinical studies evaluating DehydraTECH-CBD for hypertension. In 2023, the company expects to launch an FDA-registered Investigational New Drug (“IND”) program to formally investigate DehydraTECH-CBD, at the Phase 1b stage. And given the success witnessed in the five previous clinical trials, Lexaria believes it has effectively de-risked the upcoming FDA-registered program.
This program, Bunka wrote, is expected to dominate the company’s second half of 2023 and beyond, and “will be a major step in our maturation as a pharmaceutical company and will be our primary research focus once it begins. If it is successful, it should contribute to an increase in our corporate value and an increase in the likelihood of our reaching one or more commercial agreements within the pharmaceutical industry.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology
- The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results
- This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications
- These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)
- Currently, Lexaria is prioritizing research on DehydraTECH-CBD as a potential treatment for hypertension
Recent advancements in drug delivery techniques have improved, among others, the efficiency and safety of therapeutic treatments and active pharmaceutical ingredients (“APIs”). In fact, analyzing these improvements through the findings obtained by Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, demonstrates the progress is remarkable. Headquartered in Kelowna, British Columbia, the company developed and patented the DehydraTECH(TM) drug delivery platform technology, which is essentially an additional step easily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical lipophilic (fat-soluble) products.
“This step involves mixing the active ingredient as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors,” explains Lexaria’s website (https://nnw.fm/N4ThD ).
According to the company’s extensive studies, its patented DehydraTECH(TM) technology has been shown to enhance the bioavailability (the proportion of the ingested drug that enters the bloodstream) of APIs and increase brain absorption by up to 17x, with the effects felt in minutes (https://nnw.fm/1yBkk ). Other proven benefits include the fact that APIs processed using the technology platform are rendered largely flavorless and odorless, meaning manufacturers no longer have to add sweeteners or chemical masking agents. As a result and using DehydraTECH, they can create low-sugar products with fewer calories while avoiding the use of excessive artificial sweeteners. This is particularly positive, considering that recent studies suggest that consumption of excessive artificial sweeteners predisposes consumers to elevated blood sugar levels and raises their risk of developing stroke or heart disease (https://nnw.fm/zbozv ).
The above DehydraTECH-related findings are part of Lexaria’s extensive repository of positive results generated by its ongoing research and development (“R&D”) program. This program focuses on the development of product candidates across four main segments, which are intended to eventually serve as the platform’s commercialization avenues. These include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed nicotine delivered via non-combustive methods; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules, including antiviral drugs, hormone treatment, phosphodiesterase inhibitors, and more; and hemp-derived CBD applications for consumer packaged goods (“CPG”).
To date, Lexaria has undertaken multiple studies aimed at improving the commercialization prospects of the platform. “Our applied R&D programs completed since [our up-list to the Nasdaq exchange and capital raise in 2021] have yielded almost entirely positive results – a crucial accomplishment as we prepared to use those results to reinforce our outreach strategy to potential corporate partners,” CEO Chris Bunka stated in his annual letter to shareholders published January 2023 (https://nnw.fm/IBJEn ).
Bunka added that the applied R&D “is paying off in spades” because the company is currently engaged in active discussions with several multi-billion dollar companies around the world for the potential use of its DehydraTECH technology in their commercial products pursuits. And while the company cannot disclose the identities of these potential partners prior to the signing of definitive agreements, stakeholders and shareholders can, in the meantime, focus on the positive results of its R&D program, which are bellwethers of potential success.
For instance, in a recent diabetes animal model study, DIAB-A22-1, Lexaria reported at least three positive outcomes, including weight loss in obese diabetic-conditioned animals, a statistically significant improvement in locomotor activity, statistically significant reductions in triglyceride levels (high levels in the blood can suggest the onset of diabetes), and increased levels of HDL cholesterol, the ‘good’ kind of cholesterol (https://nnw.fm/KQjBK ).
These findings are the latest in a series of studies evaluating DehydraTECH-CBD as a potential treatment for a number of conditions, including diabetes, dementia, epilepsy, and hypertension, with the latter being the company’s primary and most advanced R&D program in this pipeline. To date, Lexaria has undertaken five human clinical studies evaluating DehydraTECH-CBD for hypertension. In 2023, the company expects to launch an FDA-registered Investigational New Drug (“IND”) program to formally investigate DehydraTECH-CBD, at the Phase 1b stage. And given the success witnessed in the five previous clinical trials, Lexaria believes it has effectively de-risked the upcoming FDA-registered program.
This program, Bunka wrote, is expected to dominate the company’s second half of 2023 and beyond, and “will be a major step in our maturation as a pharmaceutical company and will be our primary research focus once it begins. If it is successful, it should contribute to an increase in our corporate value and an increase in the likelihood of our reaching one or more commercial agreements within the pharmaceutical industry.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)